Adhoc: Sandoz Group AG: Sandoz launches TYRUKO® (natalizumab-sztn) in US, as first and only multiple sclerosis biosimilar

Sandoz Group AG / Key word(s): Market Launch Sandoz launches TYRUKO® (natalizumab-sztn) in US, as first and only multiple sclerosis biosimilar 17-Nov-2025 / 07:00 CET/CEST Release of an ad hoc ann…

Weiterlesen auf der Quellseite

Ähnliche Beiträge